Evidence of the syndrome of rapid onset end-stage renal disease (SORO-ESRD) in the acute kidney injury (AKI) literature – preventable causes of AKI and SORO-ESRD – a call for re-engineering of nephrology practice paradigms

Onuigbo, Macaulay

doi:10.3109/0886022x.2013.800459

Cited by 14 publications

(12 citation statements)

References 24 publications

(65 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Among the various risk factors, CCI score ≥4 points has the highest predictive value. In addition to correcting the renal artery stenosis, the optimal treatment of hypertension, diabetes mellitus, cerebrovascular diseases and other accompanying diseases can really improve the prognosis of patients; before the therapeutic regimen is developed for ARAS patients, the comorbidity of patients must be taken into full account, and the individualized therapeutic regimen should be developed (24–26). …”

Section: Discussionmentioning

confidence: 99%

Percutaneous renal artery stent implantation in the treatment of atherosclerotic renal artery stenosis

Hu¹,

Zhang²,

Wang³

et al. 2018

Exp Ther Med

View full text Add to dashboard Cite

We aimed to investigate the clinical curative effect of percutaneous renal artery stent implantation (PTRAS) in the treatment of atherosclerotic renal artery stenosis (ARAS), and to analyze the factors influencing the curative effect of PTRAS. A total of 230 patients with unilateral or bilateral renal artery stenosis were retrospectively analyzed. According to whether adverse cardiogenic or nephrogenic events occurred, 230 patients were divided into two groups to analyze the risk factors of adverse cardiogenic or nephrogenic events. The blood pressure of patients at each time-point after operation was decreased significantly compared with that before operation (P<0.01). The levels of serum creatinine (SCr) at 24 h and 36 months after PTRAS were slightly increased compared with that before operation (P>0.05). The estimated glomerular filtration rate (eGFR) at each time-point after operation was slightly decreased compared with that before operation, but the difference was not statistically significant (P>0.05). Renography showed that GFR on the side of stent implantation at 36 months after PTRAS had no significant change compared with that before operation (P>0.05), but GFR on the unaffected side without receiving PTRAS was significantly increased compared with that before operation (P=0.0014). During the 36-month follow-up, there were a total of 56 cases of adverse cardiogenic or nephrogenic events. Multivariate regression analysis results showed that adverse cardiogenic or nephrogenic events after PTRAS were obviously associated with age (≥65 years old), Charlson comorbidity index (CCI) score (≥2 points), diabetes mellitus, stroke and congestive heart failure (CHF) (P<0.05). In conclusion, PTRAS can effectively control the blood pressure and reduce the types of antihypertensive drugs used by patients with ARAS, but it has no definitely protective effect on renal function. Age (≥65 years old), CCI score (≥2 points), diabetes mellitus, stroke and CHF are risk factors leading to adverse cardiogenic or nephrogenic events after PTRAS.

show abstract

Section: Discussionmentioning

confidence: 99%

Percutaneous renal artery stent implantation in the treatment of atherosclerotic renal artery stenosis

Hu¹,

Zhang²,

Wang³

et al. 2018

Exp Ther Med

View full text Add to dashboard Cite

show abstract

“…Our recent review of the AKI literature, 1975-2010, had unearthed 16 individual AKI reports that described patients with features consistent with our working diagnosis of SORO-ESRD. [215] Emphatically, an accompanying editorial to one of these 16 studies, published in the Quarterly Journal Of Medicine in 1996, had referred to similar observations of ESRD rapidly following AKI in patients seen at The General Infirmary at Leeds, United Kingdom as “acute irreversible renal failure”. [16] We have concluded that this indeed was a very apt description of the syndrome after which we had coined the new name, the syndrome of rapid onset end stage renal disease, or SORO-ESRD, in 2010.…”

Section: Discussionmentioning

confidence: 99%

“…[16] We have concluded that this indeed was a very apt description of the syndrome after which we had coined the new name, the syndrome of rapid onset end stage renal disease, or SORO-ESRD, in 2010. [2111215]…”

Section: Discussionmentioning

confidence: 99%

“…[211121517181920] SORO-ESRD accounted for 34% of the incident ESRD patients in a Mayo Clinic chronic ESRD population,[21112] 9% of a Northern California incident ESRD population,[17] 12.6% of the Seattle Washington Veterans Affairs incident ESRD population[18] and 16% of the Canadian incident ESRD population,[1920] respectively. The implications of this phenomenon of the SORO-ESRD with regards to ESRD care planning, AV Fistula first programs and overall CKD care in general, are huge and warrant further study.…”

Section: Discussionmentioning

confidence: 99%

“…[24] Renoprevention is the preemptive withholding of nephrotoxics including RAAS blockers, the aggressive prevention of perioperative hypotension, the avoidance or minimalization of nephrotoxic exposure from iodinated contrast and relevant antibiotics, during critical illness and in the peri-operative period. [15242526] Such a paradigm, it is hoped, will consequently lead to less AKI events and therefore potentially less SORO-ESRD, better patient outcomes and significant dollar savings as we have demonstrated in a recent analysis in the critical care unit of a Northwestern Wisconsin Mayo Clinic Health System hospital. [1525] Such needed paradigm shifts would constitute major rethinking in current nephrology practices, a form of nephrology practice reengineering.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Syndrome of rapid onset end stage renal disease in incident Mayo Clinic chronic hemodialysis patient

Onuigbo

Musso

2014

Indian J Nephrol

View full text Add to dashboard Cite

Despite decades of research, a full understanding of chronic kidney disease (CKD)-end stage renal disease (ESRD) progression remains elusive. The common consensus is a predictable, linear, progressive and time-dependent decline of CKD to ESRD. Acute kidney injury (AKI) on CKD is usually assumed to be transient, with recovery as the expected outcome. AKI-ESRD association in current nephrology literature is blamed on the so-called “residual confounding.” We had previously described a relationship between AKI events and rapid onset yet irreversible ESRD happening in a continuum in a high-risk CKD cohort. However, the contribution of the syndrome of rapid onset-ESRD (SORO-ESRD) to incident United States ESRD population remained conjectural. In this retrospective analysis, we analyzed serum creatinine trajectories of the last 100 consecutive ESRD patients in 4 Mayo Clinic chronic hemodialysis units to determine the incidence of SORO-ESRD. Excluding 9 patients, 31 (34%) patients, including two renal transplant recipients, had SORO-ESRD: 18 males and 13 females age 72 (range 50-92) years. Precipitating AKI followed pneumonia (8), acutely decompensated heart failure (7), pyelonephritis (4), post-operative (5), sepsis (3), contrast-induced nephropathy (2), and others (2). Time to dialysis was shortest following surgical procedures. Concurrent renin angiotensin aldosterone system blockade was higher with SORO-ESRD - 23% versus 5%, P = 0.0113. In conclusion, SORO-ESRD is not uncommon among the incident general US ESRD population. The implications for ESRD care planning, AV-fistula-first programs, general CKD care and any associations with renal ageing/senescence warrant further study.

show abstract

Serum Creatinine Trajectories in Kidney Disease

Onuigbo¹,

Agbasi²,

Oguejiofor³

et al. 2016

Biomarkers in Kidney Disease

View full text Add to dashboard Cite

Evidence of the syndrome of rapid onset end-stage renal disease (SORO-ESRD) in the acute kidney injury (AKI) literature – preventable causes of AKI and SORO-ESRD – a call for re-engineering of nephrology practice paradigms

Cited by 14 publications

References 24 publications

Percutaneous renal artery stent implantation in the treatment of atherosclerotic renal artery stenosis

Percutaneous renal artery stent implantation in the treatment of atherosclerotic renal artery stenosis

Syndrome of rapid onset end stage renal disease in incident Mayo Clinic chronic hemodialysis patient

Serum Creatinine Trajectories in Kidney Disease

Contact Info

Product

Resources

About